Video Experimental Relacionado
Updated: May 5, 2026
08:24
Preparation and Characterization of Novel HDL-mimicking Nanoparticles for Nerve Growth Factor Encapsulation
Published on: May 22, 2017
7.8K
Lipoproteína como objetivo farmacológico: premisas, promesas y perspectivas
Antonio Greco1, Simone Finocchiaro1, Marco Spagnolo1
1Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico-San Marco," University of Catania, Italy.
Circulation
|February 10, 2025
Resumen
La lipoproteína (a) [Lp (a) ] es un factor de riesgo potente y genéticamente determinado para la enfermedad cardiovascular aterosclerótica. La identificación de individuos con altos niveles de Lp (a) puede orientar las estrategias preventivas y reducir los eventos cardiovasculares.
Área de la Ciencia:
- Cardiología
- La genética
- La bioquímica
Sus antecedentes:
- La enfermedad cardiovascular aterosclerótica (ASCVD, por sus siglas en inglés) representa un importante desafío para la salud mundial.
- La lipoproteína (a) [Lp (a) ] es reconocida como un factor de riesgo independiente de la EACV, superando al colesterol LDL en aterogenicidad.
- Lp (a) contribuye a la EACV a través de mecanismos proinflamatorios y pro-trombóticos, incluida la acumulación de fosfolípidos oxidados y la interferencia con la fibrinólisis.
Objetivo del estudio:
- Para resaltar la importancia de Lp (a) como factor de riesgo cardiovascular.
- Para discutir los mecanismos subyacentes a la atherothrombosis impulsada por Lp.
- Revisar las estrategias terapéuticas actuales y emergentes para la reducción de la Lp.
Principales métodos:
- Revisión de estudios genéticos (randomización mendeliana) y análisis de ensayos clínicos.
- Examen de las vías aterogénicas de Lp (por ejemplo, entrada en la pared de los vasos, interacciones con los receptores).
- Resumen de las investigaciones clínicas en curso sobre nuevas terapias para reducir la Lp.
Principales resultados:
- Los estudios genéticos confirman una relación causal entre la elevación de la Lp (a) y los resultados cardiovasculares.
- Lp (a) muestra una aterogenicidad significativamente mayor que la LDL en una base equimolar.
- Múltiples clases de fármacos dirigidos a Lp (a) están en desarrollo clínico, mostrando una promesa terapéutica.
Conclusiones:
- Una medición única de Lp (a) puede identificar a los individuos en riesgo debido a su base genética.
- Se prevé que la reducción terapéutica de Lp (a) reduzca el riesgo cardiovascular.
- El aumento de las pruebas de Lp (a) y los tratamientos dirigidos ofrecen una estrategia prometedora a nivel de población para la prevención de eventos cardiovasculares.
Videos de Conceptos Relacionados
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
517
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
517
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
145
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
145
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
71
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
71
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
112
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
112
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
26
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
26
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
118
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
118